[PDF] Top 20 La Educación Superior como autoformación: el caso de estudiantes transfronterizos1

... immunotherapy trials were unable to exclude subjects that did not have cerebral amyloid accu- mulation, thus leading to increased variability in cognitive outcome results and ultimately contributing to the frank ... See full document

... ’ s disease (AD) is the most common age-dependent neurodegenerative disease which impairs cognitive function and gradually causes patients to be unable to lead normal daily ...patients. BACE1 ... See full document

... the disease such as MCI (as shown by small SNRs), and therefore the impact of enrichment strategies was ...of clinical symptoms ...in clinical trials testing novel therapies and, ... See full document

... or clinical variables with the confidence that they were all collected within the same 3-month visit ...National Alzheimer’ s Coordinating Center, the National Cell Repository for Alzheimer’s ... See full document

... late-onset Alzheimer ’ s disease and related dis- orders (ADRD); however, the causes remain unknown, and no curative treatment is therefore ...’ s natural history, the surrogate markers of ... See full document

... larger clinical trials, but also the goal of normalizing aberrant Fyn activity in AD, without signifi- cantly altering its physiologic ...lung disease in patients with advanced solid tumors ...future ... See full document

... for clinical trials, the ability to capture the full range of MCI cases is ...Alzheimer’s Disease Neuroimaging Initiative (ADNI) study has extended the range of their designation of MCI cases beyond ... See full document

... ’ s disease (AD) is the leading cause of demen- tia worldwide and has been the target of clinical trials and intervention studies for many years ...earlier clinical stages of dementia ... See full document

... Alzheimer’s disease (AD) is characterized by progressive neurodegeneration and is the most common cause of ...the clinical and pathological findings from the active AD vaccine trial suggests that such ... See full document

... Alzheimer disease is the most common form of the dementia which occurs among older people above the age of ...Alzheimer’s disease once considered a rare disorder and it is now seen as a major public ... See full document

... novel drugs against ...to clinical outcome would be a major step ...γ-secretase inhibitor treatment results in a reduction in cortical, CSF, and plasma levels of Aβ ...a BACE1 inhibitor ... See full document

... past clinical trials were conducted in patients with mild-to-moderate ...AD. Disease-modifying drugs might work better in the preclinical stages of the disease, when A β and tau burden ... See full document

... neuroimaging or cognitive measures do not adequately reflect AD-related changes, then the resulting W scores become less accurate. As an example, we used different GM and WMH volumes to quantify cerebral damage, but only 2 ... See full document

... Alzheimer’s disease; ADCS-ADL, Alzheimer’s Disease Cooperative Study/Activities of Daily Living Inventory; ADCS-MCI-ADL-18, 18-item Alzheimer’s Disease Cooperative Study/Activities of Daily Living ... See full document

... of BACE1 specifically binds to the Golgi-localized γ-ear- containing ARF-binding proteins (GGAs), which mediate the recycling of BACE1 between the TGN and early endo- some ...modulate BACE1 turnover ... See full document

... neurodegenerative process [29]; alternatively, it may be related to concurrent vascular disease or vascular risk factors [30–32]. In order to exclude the possible con- founding effect of vascular risk factors on ... See full document

... The study sample encompassed data from all phases of the AD Neuroimaging Initiative (ADNI) (ADNI 1, Go and 2), a collaborative project of academic institutions and pri- vate corporations across the USA and Canada which ... See full document

... Longitudinally, we used cognitive scales and MRI scans to investigate declines in brain function (cognitive function reductions) and structure (brain volume loss). MMSE scale, commonly believed to reflect the overall ... See full document

... for Clinical Research (IZKF; Erlangen, Germany), the Swedish Brain Foundation (Hjärnfonden), and the Torsten Söderberg Foundation at the Royal Swedish Academy of ...for Alzheimer ’ s disease ... See full document

... the Clinical Neuro- chemistry Laboratory (Mölndal, Sweden) from patients who sought medical advice because of cognitive impair- ...other clinical data were available for the ...from clinical routine ... See full document